Emerald Mutual Fund Advisers Trust lifted its stake in shares of CVRx, Inc. (NASDAQ:CVRX - Free Report) by 28.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 370,813 shares of the company's stock after purchasing an additional 82,978 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 1.53% of CVRx worth $4,698,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of CVRx by 10,520.1% in the fourth quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock valued at $7,960,000 after purchasing an additional 622,370 shares in the last quarter. Emerald Advisers LLC raised its position in shares of CVRx by 47.3% in the fourth quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock valued at $7,525,000 after buying an additional 190,844 shares during the last quarter. Norges Bank acquired a new stake in CVRx during the fourth quarter worth approximately $1,411,000. Trexquant Investment LP grew its stake in CVRx by 292.9% in the 4th quarter. Trexquant Investment LP now owns 102,197 shares of the company's stock worth $1,295,000 after acquiring an additional 76,184 shares during the period. Finally, Tradewinds LLC. acquired a new position in CVRx in the 4th quarter valued at $695,000. Hedge funds and other institutional investors own 75.27% of the company's stock.
CVRx Trading Up 9.1 %
Shares of CVRX stock traded up $0.66 during mid-day trading on Friday, reaching $7.95. The company's stock had a trading volume of 409,464 shares, compared to its average volume of 316,709. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $207.15 million, a PE ratio of -2.96 and a beta of 1.34. The company's 50 day simple moving average is $9.87 and its 200-day simple moving average is $12.73. CVRx, Inc. has a 12-month low of $5.81 and a 12-month high of $18.55.
CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. On average, research analysts predict that CVRx, Inc. will post -1.91 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
CVRX has been the subject of a number of recent analyst reports. Piper Sandler lifted their price objective on CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Lake Street Capital cut their price objective on shares of CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, April 8th. William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Craig Hallum increased their price target on shares of CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Finally, Canaccord Genuity Group lowered their price objective on shares of CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $17.60.
Check Out Our Latest Stock Analysis on CVRX
CVRx Company Profile
(
Free Report)
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
Further Reading

Before you consider CVRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVRx wasn't on the list.
While CVRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.